Evidence map›Paper›PMID 38675994›Full record

ArticleViruses2024

Epidemiological Features of Human Norovirus Genotypes before and after COVID-19 Countermeasures in Osaka, Japan.

Tatsuya Shirai, Juthamas Phadungsombat, Yumi Ushikai, Kunihito Yoshikaie, Tatsuo Shioda, Naomi Sakon

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Global trends in norovirus genotype distribution among medically attended children with acute gastroenteritis, 2020-2025.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2026
    Article
  3. Phylogenetic Analyses ofMicroorganisms · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tatsuya ShiraiDepartment of Microbiology, Osaka Institute of Public Health, Osaka 537-0025, Japan.
Juthamas PhadungsombatResearch Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0001-6739-0144
Yumi UshikaiDepartment of Microbiology, Osaka Institute of Public Health, Osaka 537-0025, Japan.
Kunihito YoshikaieDepartment of Microbiology, Osaka Institute of Public Health, Osaka 537-0025, Japan.
Tatsuo ShiodaResearch Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.ORCID 0000-0002-3439-8331
Naomi SakonDepartment of Microbiology, Osaka Institute of Public Health, Osaka 537-0025, Japan.ORCID 0000-0001-7521-9654
Osaka Prefectural Institute of Public Health · JPThe University of Osaka · JP

Funding

Japan Society for the Promotion of Science JP18KK0270Japan Society for the Promotion of Science JP20K18924
6 · The paper itself

Abstract

We investigated the molecular epidemiology of human norovirus (HuNoV) in all age groups using samples from April 2019 to March 2023, before and after the COVID-19 countermeasures were implemented. GII.2[P16] and GII.4[P31], the prevalent strains in Japan before COVID-19 countermeasures, remained prevalent during the COVID-19 pandemic, except from April to November 2020; in 2021, the prevalence of GII.2[P16] increased among children. Furthermore, there was an increase in the prevalence of GII.4[P16] after December 2022. Phylogenetic analysis of GII.P31 RdRp showed that some strains detected in 2022 belonged to a different cluster of other strains obtained during the present study period, suggesting that HuNoV strains will evolve differently even if they have the same type of RdRp. An analysis of the amino acid sequence of VP1 showed that some antigenic sites of GII.4[P16] were different from those of GII.4[P31]. The present study showed high infectivity of HuNoV despite the COVID-19 countermeasures and revealed changes in the prevalent genotypes and mutations of each genotype. In the future, we will investigate whether GII.4[P16] becomes more prevalent, providing new insights by comparing the new data with those analyzed in the present study.

Indexed as

Caliciviridae InfectionsCOVID-19GenotypeNorovirusPhylogenyAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFecesFemaleGastroenteritisHumansInfantCOVID-19dual typingmolecular epidemiologynorovirus

Identifiers

PMID38675994
PMCPMC11055107
OpenAlexW4395012425

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.